Clinical Data ADA: AZ reveals oral GLP-1 data in obesity, diabetes PharmaphorumAstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.Metabolic & GLP-1Read full story pharminent June 9, 2026 (Last updated: June 11, 2026) Pharmaphorum AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA. Metabolic & GLP-1 Read full story Post navigation Previous: Pfizer’s Hympavzi secures FDA expanded indications for haemophiliaNext: ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
